Status:
RECRUITING
The Use of Leukapheresis to Support HIV Pathogenesis Studies
Lead Sponsor:
University of California, San Francisco
Conditions:
HIV
Eligibility:
All Genders
18+ years
Brief Summary
Despite the dramatic improvements that have resulted from combination antiretroviral treatment, long-term efficacy, toxicity, cost, and the requirements for life-long adherence remain as formidable ch...
Eligibility Criteria
Inclusion
- HIV seropositive
- Able to give informed consent
- Willing to undergo blood sampling and/or leukapheresis
- Meeting one of the following criteria: (1) on stable highly active antiretroviral therapy (HAART) with a recent undetectable viral load (\< 50 copies/mL) ("HAART suppressed"), (2) antiretroviral untreated with an undetectable viral load (\< 50 copies/mL) ("elite" controllers) and (3) antiretroviral untreated with a detectable viral load (\> 1000 copies/mL) ("non-controllers")
Exclusion
- Known anemia (HIV+ males Hct\<34; females Hct\<32) or contraindication to donating blood
- Blood coagulation disorder (including bleeding tendency or problems in past with blood clots)
- Platelets \< 50,000/mm3
- PTT \> 2x ULN
- INR \> 1.5
- Albumin \< 2.0 g/dL
- ALT \> 5x ULN
- AST \> 5x ULN
- Biopsy-proven or clinical diagnosis of cirrhosis
- Weight \<120 lb
- High blood pressure \> 160/100
- Low blood pressure \< 100/70
- Pregnant
Key Trial Info
Start Date :
October 26 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2033
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01161199
Start Date
October 26 2010
End Date
July 1 2033
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco General Hospital
San Francisco, California, United States, 94110